Fortress Biotech Secures $8 Million in New Funding
Fortress Biotech, Inc. (NASDAQ: FBIO) has proudly announced that it has successfully priced an $8 million registered direct offering alongside private placements. This innovative biopharmaceutical company focuses on acquiring and developing pioneering assets aimed at creating enduring shareholder value through multiple revenue channels.
Details of the Offering
Recently, Fortress Biotech entered into agreements with healthcare-focused institutional investors to issue and sell 3,939,394 shares of its common stock. Each share is priced at $1.65 and comes with warrants for future purchases. In this concurrent private placement, the same investors will also receive warrants, which allow them to buy up to 3,939,394 additional shares at an exercise price of $1.84. Importantly, these warrants can be exercised six months after issuance and will remain valid for approximately five and a half years.
Insider Participation in the Offering
In a strong vote of confidence, Fortress Biotech's Chairman, CEO, and President purchased 763,359 shares at the closing bid price. Along with this stock acquisition, the insider received warrants similar to those issued to institutional investors, further aligning the interests of the leadership with those of the shareholders.
Expected Use of Proceeds
The gross proceeds from this offering are projected to be around $8 million, before accounting for any fees or expenses. Fortress Biotech plans to leverage these net proceeds for various operational needs, including research and development, clinical trials, and potential acquisitions of new products. This plan highlights the company's commitment to expanding its portfolio and strengthening its market presence in the highly competitive biopharmaceutical sector.
Role of A.G.P./Alliance Global Partners
A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering, which is expected to conclude soon. This relationship underscores the strategic collaborations Fortress is building to advance its growth trajectory.
Registered Offering Details
The common stock linked to this offering is being conducted under an effective registration statement, as reported by the Securities and Exchange Commission (SEC). Additionally, the existing warrants tied to the shares are offered via a concurrent private placement, showcasing a well-structured approach to equity offerings.
About Fortress Biotech
Fortress Biotech, Inc. stands out as a notable player in the biopharmaceutical industry, actively seeking to acquire and develop valuable assets. The company currently has seven marketed pharmaceutical products and more than twenty development programs across a variety of therapeutic areas, including oncology and gene therapy. This diverse pipeline highlights Fortress’s commitment to maximizing shareholder value while addressing essential healthcare needs.
Partnerships and Collaborations
Fortress has formed significant partnerships with leading academic institutions and biopharmaceutical companies worldwide. These collaborations enhance the company’s capabilities in product development, aligning with its mission to embrace innovative healthcare solutions.
For Investors and Media Inquiries
If you have any questions about this offering or need general information about the company, investors can contact Jaclyn Jaffe at Fortress Biotech. For media inquiries, Tony Plohoros at 6 Degrees is available. Their insights and updates can help investors gain a clearer understanding of Fortress’s strategic direction.
Frequently Asked Questions
What does the $8 million offering aim to achieve?
The $8 million offering is designed to enhance Fortress Biotech’s operational capabilities, allowing for further investments in research and development as well as product development.
Who are the primary investors in this offering?
The primary investors consist of institutional investors with a focus on healthcare, reflecting a strategic alignment with Fortress’s market objectives.
How will the funds from this offering be utilized by Fortress?
Fortress will allocate the funds for general corporate purposes, which include ongoing research, clinical trials, and potential acquisitions of new products.
What does the insider purchase mean for shareholders?
The insider purchase signals strong confidence in the company's future, closely aligning the interests of the leadership with those of the shareholders.
What kinds of products is Fortress Biotech developing?
Fortress Biotech is involved in developing a diverse array of pharmaceutical products, particularly in the fields of oncology, rare diseases, and gene therapy.
